Share This! Tweet This! Recommend Us! Print Page
Language

Neurology

Neurology - Research

The MultiCare Neuroscience Center of Washington has been active in the search for new and innovative treatments for many of the devastating neurologic diseases that affect our community. The MultiCare Research Institute has partnered with the MultiCare Neuroscience Center of Washington to provide research opportunities to our community in many areas of neurologic science including:

Multiple Sclerosis

John Huddlestone, MD and the site are nationally recognized for excellence. He has been involved in clinical trials for more then 2 decades. Trials are conducted at South Sound’s only nationally recognized Multiple Sclerosis Center. The site has participated in trials evaluating

  • First oral medications for treatment of MS
  • Monoclonal antibody therapy in MS
  • Novel therapeutics with specific targets in MS
  • Comparison of Disease Modifying Therapies in MS
  • Long-term follow-up trials after Exposure to Investigational Products

Post-Herpetic Neuralgia pain control

Restless Leg Syndrome control of symptoms

Migraine Headache treatment and suppression

Movement Disorders treatment

Epilepsy

Two Board Certified Epileptologists, Laura Hershkowitz, DO and Laura Lynam, MD offer clinical trials to patients with epilepsy.


The Investigators in Neuroscience medicine include:

Laura Hershkowitz, DO, FACN (Principal Investigator)

John Huddlestone, MD, FAAN (Principal Investigator)

Peter Kwon, MD

Laura Lynam, MD,

Traci Ryan, MD

Yu Zhu, MD, PhD

Neurology Studies Accepting Participants

Adult - ACTH-MS Fatigue

Study Number: ACTH-MS Fatigue—The effect of ACTH (Acthar®) on measures of fatigue in patients with relapsing multiple sclerosis.

Study Info

Principal Investigator(s)John Huddlestone, MD

Study Coordinator:  Jarrod Monroe, jarrod.monroe@multicare.org, 253-403-7449

Adult - Esteem
Study Number: 109MS401—A multicenter, global, observational study to collect information on safety and to document the drug utilization of Tecfidera™ (Dimethyl Fumarate) when used in routine medical practice in the treatment of multiple sclerosis (ESTEEM) to assess the efficacy and safety of TECFIDERA in the United States.

Study Info

Principal Investigator(s)John Huddlestone, MD, FAAN

Study Coordinator:  Jarrod Monroe, jarrod.monroe@multicare.org, 253-403-7449
Adult - Chords
Study Number: MN30035—An open-label study to evaluate the effectiveness and safety of

Ocrelizumab in patients with relapsing remitting multiple sclerosis who have had a suboptimal response to an adequate course of disease-modifying treatment.

Study Info

Principal Investigator(s)John Huddlestone, MD, FAAN

Study Coordinator:  Jarrod Monroe, jarrod.monroe@multicare.org, 253-403-7449
Adult - Sun Pharma Spasticity
Study Number: CLR_09_21—A placebo-controlled randomized withdrawal evaluation of the efficacy and safety of Baclofen EF Capsules (GRS) in subjects with spasticity due to multiple sclerosis.

Study Info

Principal Investigator(s)John Huddlestone, MD, FAAN

Study Coordinator: Jarrod Monroe, jarrod.monroe@multicare.org, 253-403-7449
Adult - Colucid Gladiator
Study Number: COL MIG-305—An open-label, long-term, safety study of Lasmidttan (100 mg and 200 mg) in the acute treatment of migraine (GLADIATOR).

Study Info

Principal Investigator(s):  John Huddlestone, MD, FAAN

Study Coordinator: Tonya Stigger, tonya.stigger@multicare.org, 253-403-1208
Adult - Colucid Spartan
Study Number: COL MIG-302—A study of three doses of Lasmiditan (50 mg, 100 mg, and 200 mg) compared to placebo in the acute treatment of migraine: a randomized, double-blind, placebo-controlled parallel group study (SPARTAN).

Study Info

Principal Investigator(s)John Huddlestone, MD, FAAN

Study CoordinatorTonya Stigger, tonya.stigger@multicare.org, 253-403-1208
Adult - Evidera Observational Migraine
Study Number: 20150133—A  prospective observational study to evaluate tolerability and

outcomes of prophylactic therapies in migraine.

Principal Investigator(s)John Huddlestone, MD, FAAN

Study CoordinatorTonya Stigger, tonya.stigger@multicare.org, 253-403-1208
Adult - Biogen Effect
Study Number: 109MS421—A multicenter, global, retrospective, observational study to

characterize real-world clinical outcomes in patients with relapsing-remitting multiple sclerosis treated with disease-midifying therapies (Tecfidera,
Copaxone, Aubagio or Gilenya) (EFFECT).


Study Info

Principal Investigator(s)John Huddlestone, MD, FAAN

Study CoordinatorJarrod Monroe, jarrod.monroe@multicare.org, 253-403-7449
Pediatrics - Pfizer 208469
Study Number: A0081042—A double-blind, placebo-controlled, parallel-group, multicenter study of the efficacy and safety of Pregabalin as adjunctive therapy in children one month through < 4 years of age with partial onset seizures.

Study Info

Principal Investigator(s)Stephen Phillips, MD

Study CoordinatorCassidy Canorro, cassidy.canorro@multicare.org, 253-403-9348
Pediatrics - Pfizer A0081105
Study Number:

A0081105—A randomized, double-blind, placebo-controlled, parallel group,
multicenter trial of Pregabalin as adjunctive therapy in pediatric and adult subjects with primary generalized tonic-clonic seizures.


Study Info

Principal Investigator(s):  Stephen Phillips, MD

Study CoordinatorCassidy Canorro, cassidy.canorro@multicare.org, 253-403-9348
Pediatrics - Pfizer 207748
Study Number: A0081106—A 12-month open-label study to evaluate the safety and tolerability of Pregabalin as adjunctive therapy in pediatric subjects one month to 16 years of age with partial onset seizures and primary generalized tonic-clonic seizures.

Study Info

Principal Investigator(s):  Stephen Phillips, MD

Study CoordinatorCassidy Canorro, cassidy.canorro@multicare.org, 253-403-9348